Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,321 to 1,340 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Prospects in the management of patients with follicular lymphoma beyond first-line therapy. | Haematologica | 2022 | 34985231 | PubTator, text mining | PubMed |
| Emerging immuno-oncology targets in Myelodysplastic Syndromes (MDS). | Curr Probl Cancer | 2022 | 34980485 | PubTator, text mining | PubMed |
| SORT1/LAMP2-mediated extracellular vesicle secretion and cell adhesion are linked to lenalidomide resistance in multiple myeloma. | Blood Adv | 2022 | 34979567 | PubTator, text mining | PubMed |
| Development of Photolenalidomide for Cellular Target Identification. | J Am Chem Soc | 2022 | 34978798 | PubTator, text mining | PubMed |
| PLK1 inhibition-based combination therapies for cancer management. | Transl Oncol | 2022 | 34973570 | PubTator, text mining | PubMed |
| Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216. | J Med Chem | 2022 | 34965125 | PubTator, text mining | PubMed |
| Phase Ib trial of lenalidomide as post-remission therapy for older adults with acute myeloid leukemia: Safety and longitudinal assessment of geriatric functional domains. | J Geriatr Oncol | 2022 | 34955443 | PubTator, text mining | PubMed |
| Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta-analysis of randomized clinical trials. | Hematol Oncol | 2022 | 34940983 | PubTator, text mining | PubMed |
| Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1. | Blood | 2022 | 34936696 | PubTator, text mining | PubMed |
| Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection. | Clin Cancer Res | 2022 | 34862247 | PubTator, text mining | PubMed |
| The Effects of Benoxacor on the Liver and Gut Microbiome of C57BL/6 Mice. | Toxicol Sci | 2022 | 34850242 | PubTator, text mining | PubMed |
| A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. | Bioorg Chem | 2022 | 34838332 | PubTator, text mining | PubMed |
| EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma. | Cancer Discov | 2022 | 34772733 | PubTator, text mining | PubMed |
| MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma. | Blood Adv | 2022 | 34768284 | PubTator, text mining | PubMed |
| IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies. | Curr Opin Hematol | 2022 | 34743084 | PubTator, text mining | PubMed |
| Ligands for cereblon: 2017-2021 patent overview. | Expert Opin Ther Pat | 2022 | 34704527 | PubTator, text mining | PubMed |
| Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment. | Haematologica | 2022 | 34670358 | PubTator, text mining | PubMed |
| Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives. | Med Res Rev | 2022 | 34633088 | PubTator, text mining | PubMed |
| INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. | Cancer Discov | 2022 | 34544752 | PubTator, text mining | PubMed |
| Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine. | Blood Adv | 2022 | 34500459 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=67